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Abstract 
Background. Priapism is unwanted painful penile erection that affects about 36% of boys and 
men with sickle cell disease most of whom have sickle cell anemia. Clinically, priapism could be 
stuttering, minor or major. The first two types are mild, last < 4 hours, are usually treated at 
home, have good prognosis with normal sexual function. The major type of priapism lasts > 4h, 
associated with severe pain, requires hospitalization; often does not respond to medical treatment 
and may require shunt surgery. Untreated major priapism and surgical intervention often cause 
impotence. In this study we report our 15 year experience in treating adult patients with sickle 
cell disease and major priapism with blood exchange transfusion after being refractory to other 
medical therapies. Methods. Adult male African Americans patients with sickle cell disease and 
major priapism were enrolled in this study and followed for 15 years. A Haemonitics V-50 
machine was initially used for whole blood exchange and was later replaced with Cobe Spectra 
machine for RBC exchange.  Results. We used 239 blood exchanges requiring 1,136 RBC units. 
We maintained a post-exchange hemoglobin level of about 10 g/dL and hemoglobin S level < 
30%. None of the patients had any neurological complications such as headache, seizures, 
neurological deficits or obtundation post-exchange. Conclusion. Together, the data indicate that 
blood exchange transfusion for the treatment of patients with sickle cell disease and major 
priapism is efficacious and safe. 
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Introduction 
  
Priapism is unwanted and sustained painful erection lasting 4 or more hours. It is a common 
complication of sickle cell disease (SCD) affecting 89% of males with at least one episode of 
priapism by the time they are 20 years-old [1]. It is most common in patients with SS, who 
account for approximately 80% to 90% of reported cases [2-5]. However, it does occur in all 
forms of SCD including Hb SC disease, sickle thalassemia, and in sickle trait [2, 6].  
 Clinically, priapism may be stuttering, minor, or major. Stuttering priapism is the occurrence of 
short, repetitive, and reversible painful episodes with detumescence occurring within < 4 hours 
after the onset of erection. This pattern has a good prognosis and is associated with normal 
sexual function and rarely requires medical intervention. The prevalence of stuttering priapism 
varies from approximately 2% up to 60% of men and boys with SCD according to different 
reports [5, 7, 8]. Minor priapism is isolated and infrequent episodes of painful erection that last < 
4 hours and do not require medical intervention. Major priapism, however, is a prolonged 
episode of painful erection lasting longer than 4 hours and that often requires hospitalization, 
with medical and/or surgical intervention, Partial or total impotence is often associated with 
major episodes of priapism. 
 Anatomically, priapism may be bicorporal or tricorporal. Magnetic resonance imaging of the 
penis can differentiate these two patterns. Bicorporal priapism involves both corpora cavernosa 
and is common in children with stuttering pattern. This pattern has a good prognosis and is 
associated with normal sexual function. Tricorporal priapism involves both corpora cavernosa 
and the corpus spongiosum and is more common in older patients. It is a painful erection that 
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may last several days or weeks and may be followed by complete or partial impotence. Its 
prevalence varies between 6.5% [5] and 38% [7] of men with SCD. 
Management of priapism is highly controversial. Controlled studies are lacking, therapeutic 
approaches are controversial and often conflicting, and medical and surgical therapies fail in 
most patients. The major goals of treatment include pain relief and prevention of impotence. 
Stuttering and minor episodes of priapism usually last less than 4 hours and are often treated at 
home with analgesics, benzodiazepines, or pseudoephedrine and do not require treatment at the 
ED or hospital. Management of major priapism include, among other things, penile aspiration, 
irrigation with epinephrine, hydroxyurea, hormonal therapy, bicalutamide, hydralazine, 
sildenafil, oxygen, hyperhydration, exchange transfusion and shunt surgery with variable and 
inconsistent results [9-14]. Moreover, case reports of 7 children [13, 14] described acute 
neurological events following exchange transfusion for priapism thus limiting enthusiasm for 
further trials of this therapy. The purpose of this study is to describe the safety and efficacy of 
239 blood exchange transfusions that were performed between 1985 and 2009 for 10 patients 
with SCD and recurrent major episodes of priapism.   
 
 
 
Materials and Methods 
 
Patients. The ten patients enrolled in this study were adult male African Americans who had 
major priapism not responsive to standard medical treatment that included analgesics, 
benzodiazepines, penile aspiration and penile irrigation with epinephrine. They were followed up 
from January 1985 through June 2009.. Two of the patients had blood exchange for other 
complications of SCD in addition to major priapism as described in Results. The Sickle Cell 
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center was supported by the Sickle Cell Program of the Department of Health of the 
Commonwealth of Pennsylvania for the Philadelphia Region. Written consent was obtained from 
the patients for enrollment in the program. The Department of Health required the submission of 
quarterly reports describing the activities of our center. These included, among other things, the 
number of admissions to the Emergency department, admissions to the hospital, clinic visits, 
types of SCD, complications and management. The program and its various activities were 
approved by the IRB. Some of lab data in this study, however, were obtained retrospectively 
from the patients’ records.  
 
Lab Data. Hematological data were obtained by routine methods, SCD types were initially 
determined by solubility testing, hemoglobin electrophoresis in alkaline and acidic media, Thin 
layer isoelectric focusing or by high-performance liquid chromatography (HPLC) and later 
followed by gel electrophoresis. Hemoglobin F determination was by the alkaline denaturation 
method [15] or by HPLC. Alpha genotypes and βS haplotypes were determined as described 
previously [16, 17].  
 
Priapism. All the ten patients described had major priapism that lasted longer than 4 hours and 
failed to responded to various measures before initiating blood exchange transfusion. These 
measures included penile aspiration, irrigation with epinephrine, opioid analgesia and to 
preventative measures with hydration, analgesics, benzodiazepines, pseudoephedrine, 
hydralazine, sildenafil and hydroxyurea. As will be mentioned below, some patients had 
recurrent attacks of major priapism that required preventative blood exchange transfusion every 
4-8 months or sooner if needed. 
6 
 
 
Blood Exchange Transfusion. In the 1980’s a Haemonitics V-50 machine was used for 
whole blood exchange. Aliquots of whole blood were drawn intermittently at 50-70 mL/min. 
After 500 mL were removed an equal volume of reconstituted donor red cells plus 5% albumin 
and saline were transfused. This was repeated several times until all the red cell concentrates 
were transfused [12]. More exchanges were sometimes used to bring the % of Hb S < 30%. In 
the 1990’s a Cobe Spectra machine replaced the Haemonetics V-50 and was used for RBC 
exchanges. A patient’s height, weight and desired end hematocrit (Hct) were programmed into 
Spectra’s computer to determine the exact red cell volume needed. If a patient’s Hct was < 27%, 
the exchange was programed to have an end Hct of 27%. If a patient;s Hct was between 27 and 
36%, the machine was programmed to keep the end Hct at the same pre-exchange level. No 
patient’s Hct had to be reduced below the pre-exchange level unless the patient received simple 
transfusion(s) prior to exchange. The patient’s whole blood was drawn and the red cells 
separated off and discarded. The patient’s plasma was returned with donor RBC. Red cell 
exchange protocol has been described previously [18]. For both types of exchange, sickle –
negative donor RBC were phenotyped for ABO, D, c, C, e, E and Kell antigens. The aim of each 
exchange was to bring or keep the patient’s Hb level about 10 g% and reduce Hb S to ≤ 30%. A 
low Hb/Hct in SS reduces blood viscocity and is protective [19]. When peripheral access was 
possible, two-arm procedures were used and the draw side was always an anti-cubital vein. On 
the return side , the contralateral antecubital was preferred, but a smaller vein would also suffice 
but sometomes reducing the exchange rate, When peripheral access was impossible, a dual port, 
large bore catheter (e.g. Shiley) was placed surgically.  
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Statistical analysis. The paired t test was used to compare the pre- and post-exchange 
transfusion lab data. 
 
Results 
All exchange procedures were not accompanied by any significant morbidity or complications 
during the years of follow-up. Table 1 summarizes pertinent epidemiological data and RBC 
replacements for each patient. Ages of the patients at presentation with priapism were between 
21 and 46 years and ages when last seen were between 26 and 53. All patients were followed-up 
in our sickle cell center after blood exchange as part of their longitudinal plans of management. 
.This allowed us to determine the presence of any possible immediate and delayed side effects of 
the blood exchange procedures. Patients 1 and 4 had sickle-β0-thalassemia and patient 8 had Hb 
SO Arab. Patient 2 had blood exchange transfusions both for priapism and for prevention of 
stroke with 27 of the 82 exchanges for priapism and the remaining 55 for stroke prevention. 
Similarly, patient 9 had blood exchanges for priapism and for end stage renal disease and iron 
overload with 3 of the 50 exchanges for priapism and the remaining 47 for end stage renal 
disease and iron overload. None of the patients had two α-gene deletions. Most patients were 
carriers of the Benin βS haplotype followed by the Central African Republic (CAR) haplotype. 
Patient 2 presented with unusually brisk reticulocytosis requiring more units of RBC to reduce 
Hb S < 30%. Patient 8 presented late, after 24 hours of onset of priapism. All other patients 
presented within less than 24 hours of onset of priapism. A total of 239 blood exchanges were 
performed on all patients requiring 1,136 units of RBCs.  
Table 2 shows the individual total and mean hematological parameters before and after blood 
exchange. In all cases the post-exchange parameters were significantly different from the pre-
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exchange parameters. The post-exchange Hb S was significantly less than the pre-exchange 
values (p < 0.001). The post-exchange Hb/Hct values were significantly higher than the pre-
exchange numbers. The reasons for this were, as described in Materials and Methods, that the 
machine was calibrated to keep the end Hct at 27% or to match the pre-exchange value in case it 
is > 27%.  
Table 3 lists the clinical outcomes of priapism after the exchange procedures. Priapism resolved 
in the majority of the patients. Failure to respond to blood exchange transfusion occurred in two 
patients (patients 5 and 8) who required shunt surgery and penile implant due to impotence. Two 
patients (patient 1 and 2) required blood exchange on a chronic basis.  
 
Discussion. 
The most important aspect of this study is the safety and efficacy of blood exchange transfusion 
for the treatment of major episodes of priapism due to SCD. None of the patients had two α-gene 
deletions, a situation similar to the lack of two α-gene deletions in patients with SCD and stroke 
[20]. The genotype/phenotype relationship is an important aspect of sickle cell disease. The CAR 
haplotype, for example, is known to be associated with severe SCD. In the patients described in 
this study there seems to be an association of the Benin haplotype with priapism. The number of 
the patients studied, however, is too small to make reliable conclusions and more studied are 
needed to clarify the genotype/phenotype relationships in SCD.   None of the patients described 
experienced serious side effects. Patient 10 had genitofemoral neuralgia characterized by pain 
and burning sensation in the perineum and the adjacent area of the scrotum. This condition is a 
common cause of pelvic and low abdominal pain in the general population [21, 22]. To the best 
of our knowledge, however, this has not been described in patients with SCD or, most likely; it 
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could have been considered as a manifestation of sickle cell pain. Pathophysiologically, the 
swelling of the penis and the adjacent area of the perineum could have exerted pressure on the 
genital branch of the genitofemoral nerve that passes with the spermatic cord to the cremasteric 
muscles with sensory innervation to the bottom of the scrotum. In women this genital branch 
innervates the lower part of  the uterus and the labia majora. This neuropathic pain in this patient 
resolved gradually over 2-3 months.  
An association between blood exchange transfusion for priapism due to SCD and severe 
neurologic events including severe headache, seizures, focal neurological deficits and 
obtundation has been made [13, 14].  This association has been named the ASPEN syndrome 
(Association of Sickle cell disease, Priapism, Exchange transfusion and Neurologic events). All 
seven patients described were children ages 7 to 13 years. Imaging studies (computed 
tomography, MRI or cerebral arteriography) in 5 of the 6 patients described by Rackoff et al. 
[13] demonstrated vascular abnormalities, including irregularity, stenosis, and complete 
occlusion of vessels. The patient described by Siegel et al. [14] had normal cerebral computed 
tomography but MRI and cerebral arteriography were not done. Moreover, the post-exchange Hb 
levels in these patients were dangerously too high for patients with SS as shown in Table 4 and  
Figure 1, In addition the post-exchange Hb values of our patients were significantly lower than 
those in the children with the so called ASPEN syndrome (Table 4). Most notably, the Hb level 
of the patient described by Siegel et al. (Table 4) increased by over 100% indicating sudden 
expansion of the blood volume and the associated increase in whole blood viscosity. Thus it is 
the post-exchange whole blood viscosity together with the cerebral vessel abnormalities that are 
the real cause of the ASPEN syndrome and not the exchange procedure in itself. The situation is 
similar to the fatal outcome of an adult patient with SS who was hyper-transfused rapidly to a Hb 
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level over 10 g/dL [23]. It is important to note that although the Hct is the major determinant of 
whole blood viscosity, plasma components also are important contributors to whole blood 
viscosity. Thus in SCD the inflammatory meditators in plasma and the increased levels of 
fibrinogen, other coagulation factors and immunoglobulins worsen whole blood viscosity. This 
dual cause of blood viscosity was reported in a patient with SS and acute chest syndromes (ACS) 
where blood exchange transfusion was not effective in resolving the ACS despite the reduction 
of Hb S to < 30% [24].  Plasmapheresis following blood exchange transfusion in this patient was 
effective in resolving the ACS [24].   
In summary, our study demonstrates the safety and efficacy of blood exchange transfusion for 
patients with major priapism due to SCD provided the procedure is calibrated to keep the post-
exchange Hb level about 10 g/dL thus avoiding the induction of iatrogenic whole blood hyper-
viscosity and its serious sequelae. Future controlled trials using blood exchange transfusion to 
abort acute major priapism and the use of HU as a preventative major are needed. Moreover, the 
multi-center study of HU in SS (MSH) considered recurrent major priapism an acute painful 
crisis that meets the criteria for inclusion in the study [25]. Thus controlled trials to treat 
recurrent major priapism with HU vs standard medical treatment with or without blood exchange 
transfusion are needed. 
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Legend to Figure 
 
The Effect of hematocrit on whole blood viscosity. Hematocrit > 30 % in sickle cell disease 
increases whole blood viscosity significantly compared to normal. From Ballas SK. Sickle Cell 
Pain, 2nd Ed. IASP Washington, DC 2014 
  
 
Table I. Characteristics of the Patients with Priapism who Required Red Blood Cell 
Exchange 
Patient # Age at First 
RBC 
Exchange 
Age Last 
Seen 
Diagnosis α-
Genotype 
βS-Haplotype # of  
Exchanges 
Total RBC 
Exchanged 
1 38 53 S-β0-Thal -α/αα Sen, Atypical 58 282 
2 21 30 SS αα/ αα Ben, Atypical 82* 528* 
3 28 29 SS αα/ αα Ben, Ben 1 3 
4 21 26 S-β0-Thal αα/ αα Sen, Atypical 19 76 
5 32 40 SS αα/ αα Ben, CAR 19 64 
6 25 45 SS αα/ αα Ben, Ben 5 44 
7 27 27 SS αα/ αα Ben, CAR 3 16 
8 46 57 Hb SO 
Arab 
αα/ αα Sen, Atypical 1 8 
9 23 28 SS αα/ αα Ben, CAR 50† 105† 
10 26 30 SS -α/αα Ben, CAR 1 10 
  
Total 
 
239** 
 
1,136** 
Ben = Benin; CAR = Central African Republic; RBC = Red blood cell; Sen = Senegal; SS = Sickle cell 
anemia; S-Thal = Sickle thalassemia 
* 27 of the 82 blood exchanges and 157 of the RBC exchanged were for priapism and the remaining 55 
exchanges and 371 RBC exchanged were for stroke prevention. 
† 3 of the 50 exchanges and 21 of the RBC exchanged were for priapism and the remaining 47 exchanges  
and 84 RBC exchanged were for end stage renal disease and iron overload. 
** 137 of the 239 blood exchanges and 681 of the RBC exchanged were for priapism and the remaining 
102 exchanges  and 455 RBC exchanged were for other indications as mentioned above.  
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Table II. Hematological Parameters of the Patients Studied Before and After Red Blood Cell 
Exchange 
 
Patient # Hb g/dl* Hct %* % Hb S* 
Pre-Exchange Post-Exchange Pre-Exchange Post-Exchange Pre-Exchange Post-Exchange 
1 (28) 9.8 ± 1.0 (25) 10.6 ± 1.1 (25) 29.7 ± 3.4 (28) 31.5 ± 3.6 (25) 72.1 ± 
18.1 
(26) 36.8 ± 8.6 
2 (71) 7.7 ± 1.0 (69) 9.2 ± 1.1 (71) 23.0 ± 3.1 (70) 27.0 ± 3.2 (55) 48.0 ± 
15.6 
(55) 21.9 ± 14.3 
3 5.1 7.7 14.8 23.3 86.1 43.4 
4 (8) 9.0 ± 2.2 (12) 9.3 ± 1.2 (8) 26.8 ± 6.1 (12) 28.0 ± 3.3 (8) 50.9 ± 26.6 (8) 26.3 ± 22.4 
5 (19) 6.6 ± 0.7 (19) 8.4 ± 1.0 (19) 20.7 ± 2.9 (19) 25.2 ± 2.8 (5) 79.6 ± 5.0 (5) 46.0 ± 20.9 
6 (3) 8.7 ± 1.1 10.2 (3) 30.6 ± 4.8 31.9 30.0 18.2 
7 (2) 9.6 ± 0.2 (2) 9.8 ± 1.3 (2) 27.6 ± 0.1 (2) 28.1 ± 2.0 (2) 55.5 ± 0.7 (2) 19.9 ± 9.8 
8 8.2  8.5 23.7 24.6 50.3 N/A 
9 (32) 5.3 ± 0.9 (31) 7.5 ± 1.5 (30) 15.9 ± 3.2 (32) 21.4 ± 4.9 (2) 61.3 ± 25.9 (7) 39.2 ± 16.8 
10 9.9 10.6 26.9 29.9 75.0 37.0 
Total 
Average 
 (166) 7.6 ± 1.8 (162) 9.1 ± 1.5  (161) 22.8 ± 5.5 (167) 26.8 ± 
4.8 
(101) 55 ± 20.4 (106) 25.5 ± 16.1 
 
Hb = Hemoglobin; Hct = Hematocrit; N/A = Data not available; PLT = Platelet; WBC = white blood cell 
The pre- and post-exchange numbers that do not match are due to the fact that corresponding data could 
not be found. 
* (n) mean ± Standard Deviation; the difference between the post-exchange and pre-exchange values for 
all parameters shown in the total average row are significant with p <0.001. 
 
 
 
Table III. Clinical Outcomes of Priapism after Red Blood Cell Exchange Transfusions 
Patient Clinical Outcome 
1 Resolved but recurred every 6-8 months 
2 Resolved but recurred every 4-6 months 
3 Resolved, started on Hydroxyurea 
4 Resolved, started on Hydroxyurea 
5 Failed to respond, required surgery and penile implant, non-responder to Hydroxyurea 
6 Resolved 
7 Resolved 
8 Failed to respond, required surgery and penile implant 
9 Resolved 
10 Partial resolution, Genitofemoral neuralgia post-exchange, started on Hydroxyurea  
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Table IV. Reported Hematologic Values before and after Red Blood Cell Exchange Transfusion 
Parameter Pre-exchange Post-exchange Reference 
Hemoglobin (1) 6.3 (1)  13.5   Siegel et al. 1993 
 (6)  7.3 ± 1,4 (6) 12.1 ± 1.1 Rackoff et al. 1992 
 (166) 7.6 ± 1.8 (162) 9.1 ± 1.5 * This report 
Hematocrit N/A N/A Siegel et al. 1993 
 N/A N/A Rackoff et al. 1992 
 (161) 22.8 ± 5.5 (167) 26.8 ± 4.8 This report 
N/A: not available; * p < 0.001 compared to the values in the first two rows. 
 
 
